4.7 Article

Subcellular localisation of cyclin B, Cdc2 and p21WAF1/CIP1 in breast cancer:: association with prognosis

Journal

EUROPEAN JOURNAL OF CANCER
Volume 37, Issue 18, Pages 2405-2412

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0959-8049(01)00327-6

Keywords

CDK; CDK inhibitor; prognostic markers; immunohistochemistry

Categories

Ask authors/readers for more resources

The heterodimeric cyclin B/Cdc2 protein kinase governs entry into mitosis, and can be negatively regulated through p53-mediated transcriptional induction of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Ectopic expression of p21(WAF1/CIP1) in cultured cells has been shown previously to influence the subcellular distribution of the cyclin-dependent kinases (CDKs) including Cdc2. In this study, we have examined the subcellular localisation of Cdc2, cyclin B and p21(WAF1/CIP1) by immunohistochemistry in a well characterised series of primary breast cancers. Surprisingly, p21(WAF1/CIP1) was predominantly cytoplasmic in many of the tumours, where it was associated with high p53 levels; cytoplasmic p21(WAF1/CIP1) and high cyclin B levels were also significant predictors of poor prognosis. We conclude that breast tumorigenesis may be characterised by abnormalities in pathways determining not only levels of expression of key regulatory molecules, but also their subcellular localisation. Investigation of the subcellular distribution of cell cycle regulatory proteins, particularly p21(WAF1/CIP1) could provide valuable prognostic markers in breast cancer. (C) 2001 Elsevier Science Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available